The GRINA Factor: How a Single Protein Could Revolutionize Gastric Cancer Treatment
"New research reveals that targeting the GRINA protein may halt tumor progression, offering hope for those battling this aggressive cancer."
Gastric cancer, often diagnosed at advanced stages, remains a significant global health challenge. Current treatments, which include surgery, chemotherapy, and radiotherapy, often fall short of providing long-term survival, highlighting the urgent need for novel therapeutic targets.
Recent research has focused on understanding the molecular mechanisms that drive gastric cancer progression, with the aim of identifying specific proteins that can be targeted with new drugs. One such protein, GRINA (Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate-Associated Protein 1), has emerged as a potential key player in this process.
A new study published in the Journal of Experimental & Clinical Cancer Research sheds light on the role of GRINA in promoting gastric cancer. Researchers have found that GRINA is highly expressed in gastric cancer cells, where it modulates aerobic glycolysis—a process that fuels tumor growth—and inhibits cell death (apoptosis). This discovery opens exciting new avenues for developing targeted therapies that could significantly improve outcomes for patients with this deadly disease.
GRINA and Gastric Cancer Progression
Human gastric cancers have increased levels of GRINA, according to research published on December 12, 2018. The study reported that GRINA promotes gastric cancer growth and inhibits tumor-cell apoptosis. In GRINA-silenced cells, the pro-apoptotic protein Bax increased while the anti-apoptotic protein Bcl-2 decreased.
GRINA: The Master Regulator of Gastric Cancer Growth?
The study, led by researchers at Shanghai Jiao Tong University, explored the role of GRINA in gastric cancer by analyzing gene expression data from patient samples and conducting experiments on gastric cancer cell lines. The results revealed a strong correlation between GRINA expression and several key factors that contribute to tumor growth and spread:
- Increased cell proliferation: GRINA promotes the rapid growth of gastric cancer cells.
- Enhanced migration and invasion: GRINA empowers cancer cells to move and invade surrounding tissues.
- Inhibition of apoptosis: GRINA protects cancer cells from programmed cell death.
- Activation of aerobic glycolysis: GRINA boosts the cancer cells' ability to metabolize glucose for energy, even in the presence of oxygen (Warburg effect).
GRINA’s Metabolic Role
Reviews report that GRINA, also known as glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1, is involved in gastric-cancer metabolism. GRINA has been linked to lipid and sterol synthesis and to the modulation of aerobic glycolysis, a metabolic pattern that promotes tumor progression. Knockdown of GRINA has also been shown to inhibit PI3K/AKT/mTOR signaling and glycolytic metabolism in gastric cancer cells. Other research reports that GRINA expression is upregulated in gastric cancer, enhancing progression and suppressing apoptosis.
Limits of the Evidence
The reported association between GRINA expression and gastric cancer does not establish that GRINA alone determines patient outcomes. One study found correlations with histological differentiation, T stage, N stage, distant metastasis, blood vessel invasion, and perineuronal invasion, but not with age or gender. Its analysis relied on chi-square or Fisher’s exact tests for clinicopathological parameters and Kaplan-Meier and log-rank methods for survival curves. Separately, the study reported that GRINA promoted proliferation, migration, invasion, and cell-cycle transition, but these findings remain evidence from experimental research rather than proof of a successful treatment.
A Promising New Target for Gastric Cancer Therapy
These findings suggest that GRINA is a promising target for the development of new therapies to combat gastric cancer. By inhibiting GRINA, researchers hope to disrupt the processes that fuel tumor growth and promote cell survival. Studies are underway to explore strategies for targeting GRINA and to assess the efficacy of these approaches in preclinical models. While further research is needed, the discovery of GRINA's role in gastric cancer offers a beacon of hope for improving outcomes for patients battling this devastating disease.
From Biomarker to Therapeutic Target
A 2025 review states that gastric cancer remains deadly because of late detection and limited treatment options at advanced stages. For metastatic disease, treatment is based on chemotherapy supplemented by antibodies targeting HER2, VEGFR2, and more recently PD-1 or claudin 18.2. A 2021 bioRxiv study described GRINA as an emerging cancer-therapy target and reported upregulated GRINA mRNA and protein in gastric cancer. That study also reported a negative correlation between GRINA expression and patient survival, although it emphasized that the relationship had not been comprehensively studied.
Toward More Individualized Care
Recent gastric-cancer treatment reviews summarize pivotal clinical trials and updates in localized and metastatic disease, while highlighting developments in immunotherapy, targeted therapy, and individualized treatment. The field also faces a continuing global burden: GLOBOCAN 2022 statistics reported 968,350 new gastric-cancer cases and 659,853 deaths annually, ranking gastric cancer fifth globally for both incidence and mortality. Future research should use prospective, multicenter gastric-cancer cohorts with harmonized diagnostic criteria, measurement methods, and outcome definitions. Such studies are intended to clarify the value of body composition, inflammation, microbiota, and multi-omics information in predicting nutritional risk and treatment tolerance.
The Patient-Level Test
A September 2026 study noted that immunotherapy and molecular targeted agents have been introduced for advanced gastric cancer, but that it remains unclear whether these advances have improved survival in real-world settings. This uncertainty matters when evaluating any proposed new target, including GRINA. Experimental findings from a GRINA study reported increased Bax and decreased Bcl-2 after GRINA silencing, alongside the conclusion that GRINA promotes gastric-cancer growth and inhibits tumor-cell apoptosis. These laboratory results suggest a possible biological route for therapy, but they do not by themselves demonstrate improved survival for patients.